Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sagent Pharmaceuticals Inc Reaffirms FY 2013 Revenue Guidance; Raises Low End Of Prior FY 2013 Net Income Guidance To A Range Above Analysts' Estimates


Tuesday, 5 Nov 2013 07:00am EST 

Sagent Pharmaceuticals Inc announced that it expects net revenue for fiscal to be in the range of $230 to $250 million driven by 10 to 12 product launches and narrowed its anticipated range for reported net income for fiscal 2013 to between $24 million and $28 million. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $244 million and net income of $23 million for fiscal 2013. 

Company Quote

25.95
0.22 +0.86%
4:00pm EDT